Clinical Trials

1,503 enrolled

Prostatic Neoplasms

NCT04293393 2026-03-12

CARABELA

200 enrolled 27 charts

Phase 1 Active not recruiting

Breast Neoplasms

NCT06379217 2026-03-11

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

31 enrolled

EndocrineGenitourinary

Metastatic Neuroendocrine Prostate Cancer

NCT04931342 2026-03-10

BOUQUET

Phase 4 Active not recruiting

176 enrolled

Gynecologic

Ovarian Neoplasms

NCT03016741 2026-02-24

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

100 enrolled

Dementia, Prostatic Neoplasms, Cognitive Dysfunction, Prostatic Neoplasms, Castration-Resistant

NCT04546009 2026-02-20

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

992 enrolled

Breast Neoplasms

NCT04961996 2026-02-20

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

4,170 enrolled

Phase 1 Active not recruiting

Breast Neoplasms

NCT03332797 2026-02-13

A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

181 enrolled

Breast Neoplasms

NCT04325828 2026-02-13

YATAGARASU

31 enrolled 15 charts

Head & Neck

Salivary Gland Neoplasms

NCT05306340 2026-01-30

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

373 enrolled

Breast Neoplasms

NCT03879577 2026-01-21

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

53 enrolled 13 charts

Breast Neoplasms

NCT06734130 2026-01-21

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

25 enrolled

Prostatic Neoplasms

NCT04576455 2026-01-16

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

303 enrolled 23 charts

Breast Neoplasms

NCT04964934 2026-01-16

SERENA-6

315 enrolled

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site

NCT05296798 2026-01-16

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

922 enrolled

Breast Neoplasms

NCT06001762 2026-01-16

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

90 enrolled

Breast Neoplasms

NCT02949284 2026-01-07

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

90 enrolled

Stage II Prostate Adenocarcinoma

NCT03809000 2025-12-30

STEEL

188 enrolled 25 charts

Prostatic Neoplasms

NCT00329043 2025-12-26

Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy

64 enrolled

Prostatic Neoplasms

NCT04025372 2025-12-15

INTREPId (INTermediate Risk Erection PreservatIon Trial)

234 enrolled

Phase EARLY_PHASE1 Active not recruiting

Prostatic Neoplasms

NCT03511196 2025-12-04

Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer

17 enrolled

Prostatic Neoplasms

NCT05189457 2025-12-04

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

32 enrolled

Prostatic Neoplasms

NCT03436654 2025-11-28

Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma

102 enrolled

Prostatic Neoplasms

NCT04711252 2025-10-14

SERENA-4

1,370 enrolled

Phase NA Active not recruiting

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Skin Diseases

NCT03630666 2025-08-17

OLIGOPELVIS2

256 enrolled

Prostatic Neoplasms

NCT00567580 2025-05-09

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

1,792 enrolled 27 charts

Prostatic Neoplasms

NCT04262154 2025-04-27

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

28 enrolled

Prostatic Neoplasms

NCT03141671 2024-05-14

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

345 enrolled

Phase 2/3 Active not recruiting

Prostatic Neoplasms

NCT02221999 2023-08-29

SHPD002

250 enrolled

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT04136353 2023-07-28

DASL-HiCaP

1,100 enrolled

Prostatic Neoplasms

NCT00430183 2023-02-09

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

788 enrolled 10 charts